AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
阿斯利康阿斯利康(US:AZN) WSJ·2026-07-14 14:55

公司与行业动态 - 阿斯利康与中国的迪哲医药就一款肺癌治疗药物达成了独家全球许可协议 [1]

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion - Reportify